Search for: "Novartis Pharmaceuticals Corporation" Results 1 - 20 of 145
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Jun 2019, 5:50 pm by Stuart P. Meyer
Back in March, I reported on the breadth of comments the USPTO received in response to its new Guidance on patent subject matter eligibility. [read post]
26 Mar 2019, 1:59 pm by Stuart P. Meyer
The Pharmaceutical Research and Manufacturers of America specifically praised various aspects of the Guidance for providing clarity in areas that had been confusing. [read post]
7 Dec 2018, 2:23 pm by Lawrence B. Ebert
The outcome was reversal; Novartis wins:Novartis Pharmaceuticals Corporation and NovartisAG (collectively, Novartis) appeal the district court’sdecision to invalidate U.S. [read post]
16 May 2018, 7:17 pm by Sabrina I. Pacifici
The document detailed sums in the hundreds of thousands of dollars paid to Cohen by the pharmaceutical company Novartis, the telecommunications giant A.T. [read post]
11 May 2018, 8:59 am by Joe Consumer
We got word that a couple weeks ago, the Swiss pharmaceutical giant, Novartis, was about to change its company profile page! [read post]
6 Mar 2018, 2:10 pm by Tom Lamb
In closing this article, I will point out that in the US there still has not been any "Dear Doctor" letter sent nor any Tasigna drug label change made by Novartis Pharmaceuticals Corporation regarding atherosclerosis, despite the actions taken by its Canadian counterpart during April 2013. [read post]
6 Mar 2018, 2:10 pm by Tom Lamb
In closing this article, I will point out that as of today, nearly five years after the actions taken by Novartis Pharmaceuticals Canada Inc., in the US there still has not been any "Dear Doctor" letter nor any Tasigna drug label change made by Novartis Pharmaceuticals Corporation similar to what was done in Canada during April 2013. [read post]
27 Feb 2018, 9:12 am by Tom Lamb
We point out that there was no similar "Dear Doctor" letter sent in the US by Novartis Pharmaceuticals Corporation in 2013, nor was any similar Tasigna drug label change made by Novartis in the US back then. [read post]
7 Feb 2018, 8:39 am by Clay Hodges
What’s more alarming, the drug’s manufacturer, Novartis Pharmaceuticals Corporation, may have known about those risks and failed to disclose them to you. [read post]
17 Jan 2018, 1:37 pm
Novartis Pharmaceuticals Corporation, S233898).La prescription "off-label" d'un produit pharmaceutique est admise. [read post]
17 Jan 2018, 1:29 pm
Novartis Pharmaceuticals Corporation, S233898).Quand elles statuent en diversité, les cours fédérales veilleront à appliquer le droit des états dans sa teneur objective, sans chercher à créer de nouvelles théories juridiques. [read post]
17 Jan 2018, 1:25 pm
Novartis Pharmaceuticals Corporation, S233898).Le devoir de diligence est une des conditions centrales de l'obligation de réparer un dommage en responsabilité civile. [read post]
17 Jan 2018, 1:16 pm
Novartis Pharmaceuticals Corporation, S233898).Prévisibilité du dommage en responsabilité civile et contractuelle (droit californien) :Face à la question de savoir si un défendeur répond envers un lésé, le droit californien accorde une importance essentielle à la notion de prévisibilité. [read post]
14 Jan 2018, 6:34 am
Novartis Pharmaceuticals Corporation, S233898).Exigences en matière d'étiquetages et notices, ici de médicaments et de dispositifs médicaux Le droit des états, ici californien, protège substantiellement les consommateurs de médicaments des dangers posés par des étiquetages et des notices faux, trompeurs ou inadéquats. [read post]
14 Jan 2018, 4:00 am
Novartis Pharmaceuticals Corporation, S233898).Le producteur d'un carburant vendu en gros n'est redevable d'aucun devoir d'aviser des risques envers le consommateur final, lorsque le producteur a donné un avis adéquat au distributeur, auquel revient les tâches de conditionner et d'écouler le produit. [read post]
13 Jan 2018, 8:00 pm
Novartis Pharmaceuticals Corporation, S233898).Responsabilité civile et contractuelle (droit californien), déclaration inexacte ("misrepresentation") :En droit californien, une action en dommages-intérêts fondée sur une déclaration inexacte peut être déposée contre d'autres défendeurs que le seul fabricant du produit. [read post]
21 Nov 2017, 2:40 pm by Tom Lamb
We recommend that the FDA and [Novartis Pharmaceuticals Corporation] the manufacturer [of Entresto] more clearly communicate the full risk of hypotension, including appropriate steps for monitoring patients, and examine whether a more gradual escalation of dose to the recommended level would reduce the risk. [read post]
30 Oct 2017, 3:46 pm by Baum Hedlund
(formerly Questcor Pharmaceuticals Inc.) of California; Mallinckrodt PLC of Ireland; and United BioSource Corporation (UBC) of Delaware. [read post]
26 Jul 2017, 7:24 pm by FDABlog HPM
It was just earlier this month that FDA’s Oncologic Drugs Advisory Committee recommended that FDA approve the first gene therapy product: Novartis Pharmaceuticals Corporation’s BLA 125646 for Tisagenlecleucel for the treatment of pediatric and young adult patients 3 to 25 years of age with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia. [read post]